Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Fulgent Genetics, Inc.NASDAQ: FLGT
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows in line with its trailing trend
Q1 FY2026 cost of revenue of $49.65M rose 10.0% year over year, in line with the +9.7% change in trailing-twelve-month cost of revenue. Sequentially, it fell 2.2% from the prior quarter. Over 3 fiscal years it compounded at -8.7% a year.
Context
- Cost of revenue amounted to 59.4% of revenue in FY2025, down 2.7 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +10.0% holds above the trailing-twelve-month pace of +9.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 191.8M USD
- Year-over-year change
- +8.8%
- 4-year CAGR
- -2.9%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 191.8M | +8.8% |
| FY2024 | 2024-12-31 | 176.26M | -4.6% |
| FY2023 | 2023-12-31 | 184.76M | -26.7% |
| FY2022 | 2022-12-31 | 252.07M | +17.0% |
| FY2021 | 2021-12-31 | 215.53M | — |
Cost of Revenue vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 cost of revenue of $196.33M is the 5th highest of the 8 companies compared; the peer median is $249M.
- Its year-over-year change of +9.7% is the 6th highest of 8, against a peer median of +21.5%.
- Cost of revenue amounts to 61.3% of revenue for FLGT, versus a peer median of 34.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $939.25M | +28.9% | +21.1% | 34.7% | |
| LTM Sep 2026 | $445.18M | +36.1% | +30.7% | 34.8% | |
| LTM Jun 2026 | $437.4M | +13.2% | +11.4% | 57.1% | |
| LTM Mar 2026 | $249M | -0.1% | +7.1% | 30.0% | |
| LTM Mar 2026 | $196.33M | +9.7% | -8.7% | 61.3% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $144.53M | +21.5% | -20.9% | 31.8% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $114.19M | +39.8% | — | 28.7% |
| LTM Mar 2026 | $55.67M | -2.6% | +1.4% | 86.3% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding FLGT) | $249M | +21.5% | +9.2% | 34.7% | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
| Cost of Revenue | 215.53M | 252.07M | 184.76M | 176.26M | 191.8M |
| Gross Profit | 777.05M | 366.9M | 104.46M | 107.22M | 130.88M |
| Gross Margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Research & Development | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
| Selling, General & Admin | 75.17M | 149.99M | 130.47M | 124.35M | 160.04M |
| Operating Expenses | 101.1M | 188.37M | 299.99M | 181.13M | 221.97M |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| EBITDA | 692.04M | 217.7M | (147.45M) | (26.86M) | (45.83M) |
| EBITDA Margin | 69.7% | 35.2% | -51.0% | -9.5% | -14.2% |
| Operating Income | 675.95M | 178.53M | (195.53M) | (73.92M) | (91.1M) |
| Operating Margin | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% |
| Interest Income | 1.35M | 5.62M | 21.61M | 31.3M | 30.92M |
| Interest Expense | 0 | 1.01M | 488K | 170K | 75K |
| Other Income / Expenses | 5.08M | 5.5M | 21.44M | 21.96M | 21.07M |
| Income Before Tax | 681.03M | 184.03M | (174.09M) | (51.96M) | (70.03M) |
| Pre-Tax Margin | 68.6% | 29.7% | -60.2% | -18.3% | -21.7% |
| Income Tax Expense | 174.8M | 42.1M | 1.15M | (8.14M) | (8.39M) |
| Net Income | 507.36M | 143.4M | (167.83M) | (42.71M) | (60.51M) |
| Net Margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| EPS (Basic) | 17.13 | 4.76 | (5.63) | (1.41) | (1.97) |
| EPS (Diluted) | 16.26 | 4.63 | (5.63) | (1.41) | (1.97) |
| Weighted Avg Shares | 29.41M | 30.1M | 29.78M | 30.24M | 30.78M |
| Weighted Avg Shares (Diluted) | 30.98M | 30.96M | 29.78M | 30.24M | 30.78M |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.